Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

American Conference Institute 12th Annual Maximizing Pharmaceutical Patent Life Cycles Conference

Loeb & Loeb LLP is proud to be a sponsor of American Conference Institute’s (ACI’s) 12th Annual Maximizing Pharmaceutical Patent Life Cycles, where partner
Mark E. Waddell will serve as conference co-chair and speaker on a panel titled, "Understanding How the Patent Cliff will Re-Define the Endgame”

From the conference website:

American Conference Institute’s (ACI’s) Maximizing Pharmaceutical Patent Life Cycles conference is the pharmaceutical industry’s leading source for information and analysis on patent life cycle management for both small and now, large molecule pharmaceutical products. It is the forum where lawyers, executives and policy makers for brand name and generic manufacturers gather each year to prepare for the life cycle challenges they currently face as well as those which they anticipate.

Selected Agenda

Tuesday, October 4, 2011
8:30AM-9:30AM - Understanding How the Patent Cliff will Re-Define the Endgame

  • Defining the patent cliff
  • How will the patent cliff impact the future of the pharmaceutical industry?
    • brand-name and generic perspectives
  • Understanding how the patent cliff could unravel the balance of power established by Hatch-Waxman between brand names and generics
  • Exploring modes of innovation that will make up for patent cliff losses
    • drug delivery modalities
    • combination products
    • combined drugs
    • combined drug and device therapies
    • the future of gene patenting
    • other section 101 controversies
  • Identifying the role of biosimilars in the era of the small molecule patent cliff

George W. Johnston, Hoffmann-La Roche
Christopher A. Vellturo, Quantitative Economic Solutions, LLC
Mark E. Waddell, Loeb & Loeb LLP